<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04158141</url>
  </required_header>
  <id_info>
    <org_study_id>NRG-LU006</org_study_id>
    <secondary_id>NCI-2019-07141</secondary_id>
    <secondary_id>NRG-LU006</secondary_id>
    <secondary_id>NRG-LU006</secondary_id>
    <secondary_id>U10CA180868</secondary_id>
    <nct_id>NCT04158141</nct_id>
  </id_info>
  <brief_title>Testing the Addition of Targeted Radiation Therapy to Surgery and the Usual Chemotherapy Treatment (Pemetrexed and Cisplatin [or Carboplatin]) for Stage I-IIIA Malignant Pleural Mesothelioma</brief_title>
  <official_title>Phase III Randomized Trial of Pleurectomy/Decortication Plus Chemotherapy With or Without Adjuvant Hemithoracic Intensity-Modulated Pleural Radiation Therapy (IMPRINT) for Malignant Pleural Mesothelioma (MPM)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>NRG Oncology</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>NRG Oncology</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This trial studies how well the addition of targeted radiation therapy to surgery and the&#xD;
      usual chemotherapy treatment works for the treatment of stage I-IIIA malignant pleural&#xD;
      mesothelioma. Targeted radiation therapy such as intensity-modulated radiation therapy or&#xD;
      pencil beam scanning uses high energy rays to kill tumor cells and shrink tumors. Drugs used&#xD;
      in chemotherapy, such as pemetrexed, cisplatin, and carboplatin, work in different ways to&#xD;
      stop the growth of tumor cells, either by killing the cells, by stopping them from dividing,&#xD;
      or by stopping them from spreading. Giving targeted radiation therapy in addition to surgery&#xD;
      and chemotherapy may work better than surgery and chemotherapy alone for the treatment of&#xD;
      malignant pleural mesothelioma.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVE:&#xD;
&#xD;
      I. To detect an improvement in overall survival with the addition of adjuvant hemithoracic&#xD;
      intensity-modulated pleural radiation therapy (IMPRINT) to surgery and chemotherapy compared&#xD;
      to surgery and chemotherapy alone.&#xD;
&#xD;
      SECONDARY OBJECTIVES:&#xD;
&#xD;
      I. To determine local failure-free survival, distant-metastases-free survival, and&#xD;
      progression-free survival with the addition of adjuvant hemithoracic IMPRINT to surgery and&#xD;
      chemotherapy compared to surgery and chemotherapy alone.&#xD;
&#xD;
      II. To evaluate the treatment-related toxicities in both arms per Common Terminology Criteria&#xD;
      for Adverse Events (CTCAE) version (v)5.0.&#xD;
&#xD;
      III. To detect a clinically meaningful 10-point change in global health status mean scores at&#xD;
      9 months after randomization with the addition of adjuvant IMPRINT as compared to surgery and&#xD;
      chemotherapy alone.&#xD;
&#xD;
      EXPLORATORY OBJECTIVES:&#xD;
&#xD;
      I. To evaluate the degree of under-staging, concordant and upstaging between&#xD;
      centrally-reviewed clinical staging (based on positron emission tomography [PET], computed&#xD;
      tomography [CT] and/or magnetic resonance imaging [MRI]) and pathologic staging.&#xD;
&#xD;
      II. To identify immunologic and pathologic biomarkers as predictors of response and potential&#xD;
      targets for future combination trials.&#xD;
&#xD;
      III. To determine the magnitude of radiation dose escalation to gross residual disease based&#xD;
      on combined modality imaging and associated local control rates with dose-painting&#xD;
      intensity-modulated radiation therapy (IMRT).&#xD;
&#xD;
      IV. To determine the rate of R0/R1 and R2 resections, and type of procedures (extended&#xD;
      pleurectomy/decortication [P/D], P/D and partial pleurectomy).&#xD;
&#xD;
      V. To evaluate the trajectory of European Organization for Research and Treatment of Cancer&#xD;
      Quality of Life Questionnaire Core 30 (EORTC QLQ-Q30) and lung cancer specific module (LC13)&#xD;
      symptoms in patients treated with IMPRINT by comparing the proportion of patients who respond&#xD;
      with &quot;quite a bit&quot; or &quot;very much&quot; LC13 symptoms at 9-12 months post-randomization compared to&#xD;
      at 3 months post-randomization.&#xD;
&#xD;
      VI. To evaluate changes in health-related quality of life, functional domains, and symptoms&#xD;
      over time with the addition of adjuvant IMPRINT as compared to surgery and chemotherapy&#xD;
      alone.&#xD;
&#xD;
      OUTLINE:&#xD;
&#xD;
      STEP 1: Patients undergo P/D then within 4 to 8 weeks receive pemetrexed intravenously (IV)&#xD;
      over 10 minutes and cisplatin or carboplatin IV over 60 minutes on day 1. Patients may&#xD;
      instead receive pemetrexed IV over 10 minutes and cisplatin or carboplatin IV over 60 minutes&#xD;
      on day 1 then undergo P/D within 4 to 8 weeks after chemotherapy. The order of surgery and&#xD;
      chemotherapy is at the discretion of the treating physician.&#xD;
&#xD;
      STEP 2: Within 4 to 8 weeks from the end of Step 1 treatment, patients are randomized to 1 of&#xD;
      2 arms.&#xD;
&#xD;
      ARM I: Patients receive no treatment.&#xD;
&#xD;
      ARM II: Patients undergo 25-28 fractions IMRT or pencil beam scanning (PBS) proton therapy 5&#xD;
      days per week over 6 weeks.&#xD;
&#xD;
      After completion of study treatment, patients are followed up every 3 months for 2 years,&#xD;
      then every 6 months for 3 years.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 29, 2020</start_date>
  <completion_date type="Anticipated">July 1, 2030</completion_date>
  <primary_completion_date type="Anticipated">July 1, 2025</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall survival (OS)</measure>
    <time_frame>From the date of randomization and the date of death due to any cause, assessed up to 5 years</time_frame>
    <description>Will compare the distributions of OS between treatment arms using a one-sided stratified log-rank test (using stratification factors as strata). The rates at various timepoints (e.g., every 6 months after randomization) and medians of OS for each arm will be estimated using the Kaplan-Meier method. The associated 90% confidence interval (CI) will be calculated using Greenwood?s formula and based on a log-log transformation applied on the survival function. Hazard ratios will be estimated using a stratified Cox regression model.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Local-failure-free survival (LFFS)</measure>
    <time_frame>From randomization to local disease progression or death due to any cause, whichever occurs first, assessed up to 5 years</time_frame>
    <description>Will compare the distributions of LFFS between treatment arms using a one-sided stratified log-rank test (using stratification factors as strata). The rates at various timepoints (e.g., every 6 months after randomization) and medians of LFFS for each arm will be estimated using the Kaplan-Meier method (1958). The associated 95% CI will be calculated using Greenwood?s formula and based on a log-log transformation applied on the survival function. Hazard ratios for LFFS will be estimated using a stratified Cox regression model.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Distant-metastases-free survival (DMFS)</measure>
    <time_frame>From randomization to distant metastases or death due to any cause, whichever occurs first, assessed up to 5 years</time_frame>
    <description>Will compare the distributions of DMFS between treatment arms using a one-sided stratified log-rank test (using stratification factors as strata). The rates at various timepoints (e.g., every 6 months after randomization) and medians of DMFS for each arm will be estimated using the Kaplan-Meier method (1958). The associated 95% CI will be calculated using Greenwood?s formula and based on a log-log transformation applied on the survival function. Hazard ratios for PFS will be estimated using a stratified Cox regression model.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival (PFS)</measure>
    <time_frame>From randomization to any documented progression or death due to any cause, whichever occurs first, assessed up to 5 years</time_frame>
    <description>Will compare the distributions of PFS between treatment arms using a one-sided stratified log-rank test (using stratification factors as strata). The rates at various timepoints (e.g., every 6 months after randomization) and medians of PFS for each arm will be estimated using the Kaplan-Meier method (1958). The associated 95% CI will be calculated using Greenwood?s formula and based on a log-log transformation applied on the survival function. Hazard ratios for PFS will be estimated using a stratified Cox regression model.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of treatment-related toxicity</measure>
    <time_frame>Up to 5 years</time_frame>
    <description>Adverse events (AEs) will be graded with Common Terminology Criteria for Adverse Events (CTCAE) version 5.0. All adverse events, adverse events leading to withdrawal, interruption or modification of protocol treatment, grade &gt;= 3 adverse events, and serious adverse events will be summarized. Deaths and cause of death will be summarized. The rate of treatment-related adverse events will be reported with the frequency and severity (e.g., type, grade, and attribution) by arm.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Life (QOL)/patient-reported Outcome (PRO)</measure>
    <time_frame>Up to 5 years</time_frame>
    <description>Measured by European Organization for Research and Treatment of Cancer (EORTC) quality of life questionnaires.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Degree of under-staging, concordant and upstaging between centrally-reviewed clinical staging and pathologic staging</measure>
    <time_frame>Up to 5 years</time_frame>
    <description>For each subject, the centrally-reviewed clinical staging (based on positron emission tomography, computed tomography and/or magnetic resonance imaging) will be compared with pathologic staging to determine whether it is under-staging (clinical staging is more extensive than pathologic staging), concordant (clinical staging is same as pathologic staging), or upstaging (clinical staging is less extensive than pathologic staging). The proportion of under-staging, concordant and upstaging, along with the associated 95% confidence intervals, will be reported.</description>
  </other_outcome>
  <other_outcome>
    <measure>Association between radiation dose to gross residual disease and local control</measure>
    <time_frame>Up to 5 years</time_frame>
    <description>Gross residual disease and local failure will be analyzed as competing risk data (death without gross residual disease or death without local failure as the respective competing event). Association between radiation dose to gross residual disease and local failure will be evaluated similarly in multivariable analyses using Fine-Gray regression model.</description>
  </other_outcome>
  <other_outcome>
    <measure>Rate of R0/R1 and R2 resections, by type of procedures (extended pleurectomy/decortication (P/D), P/D and partial pleurectomy)</measure>
    <time_frame>Up to 5 years</time_frame>
    <description>Proportions of R0/R1 and R2 resections, by type of procedures (extended pleurectomy/decortication (P/D), P/D and partial pleurectomy), along with 95% confidence intervals, will be reported.</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">150</enrollment>
  <condition>Pleural Biphasic Mesothelioma</condition>
  <condition>Pleural Epithelioid Mesothelioma</condition>
  <condition>Stage I Pleural Malignant Mesothelioma AJCC v8</condition>
  <condition>Stage IA Pleural Malignant Mesothelioma AJCC v8</condition>
  <condition>Stage IB Pleural Malignant Mesothelioma AJCC v8</condition>
  <condition>Stage II Pleural Malignant Mesothelioma AJCC v8</condition>
  <condition>Stage IIIA Pleural Malignant Mesothelioma AJCC v8</condition>
  <arm_group>
    <arm_group_label>Arm I (Step 1: chemotherapy, P/D: Step 2: no treatment)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>STEP 1: Patients undergo P/D then within 4 to 8 weeks receive pemetrexed IV over 10 minutes and cisplatin or carboplatin IV over 60 minutes on day 1. Patients may instead receive pemetrexed IV over 10 minutes and cisplatin or carboplatin IV over 60 minutes on day 1 then undergo P/D within 4 to 8 weeks after chemotherapy. The order of surgery and chemotherapy is at the discretion of the treating physician.&#xD;
STEP 2: Patients receive no treatment.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm II (Step 1: chemotherapy, P/D, Step 2: IMRT/PBS)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>STEP 1: Patients undergo P/D then within 4 to 8 weeks receive pemetrexed IV over 10 minutes and cisplatin or carboplatin IV over 60 minutes on day 1. Patients may instead receive pemetrexed IV over 10 minutes and cisplatin or carboplatin IV over 60 minutes on day 1 then undergo P/D within 4 to 8 weeks after chemotherapy. The order of surgery and chemotherapy is at the discretion of the treating physician.&#xD;
STEP 2: Within 4-8 weeks from the end of Step 1 treatment, patients undergo 25-28 fractions IMRT or PBS proton therapy 5 days per week over 6 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Carboplatin</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Arm I (Step 1: chemotherapy, P/D: Step 2: no treatment)</arm_group_label>
    <arm_group_label>Arm II (Step 1: chemotherapy, P/D, Step 2: IMRT/PBS)</arm_group_label>
    <other_name>Blastocarb</other_name>
    <other_name>Carboplat</other_name>
    <other_name>Carboplatin Hexal</other_name>
    <other_name>Carboplatino</other_name>
    <other_name>Carboplatinum</other_name>
    <other_name>Carbosin</other_name>
    <other_name>Carbosol</other_name>
    <other_name>Carbotec</other_name>
    <other_name>CBDCA</other_name>
    <other_name>Displata</other_name>
    <other_name>Ercar</other_name>
    <other_name>JM-8</other_name>
    <other_name>Nealorin</other_name>
    <other_name>Novoplatinum</other_name>
    <other_name>Paraplatin</other_name>
    <other_name>Paraplatin AQ</other_name>
    <other_name>Paraplatine</other_name>
    <other_name>Platinwas</other_name>
    <other_name>Ribocarbo</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cisplatin</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Arm I (Step 1: chemotherapy, P/D: Step 2: no treatment)</arm_group_label>
    <arm_group_label>Arm II (Step 1: chemotherapy, P/D, Step 2: IMRT/PBS)</arm_group_label>
    <other_name>Abiplatin</other_name>
    <other_name>Blastolem</other_name>
    <other_name>Briplatin</other_name>
    <other_name>CDDP</other_name>
    <other_name>Cis-diammine-dichloroplatinum</other_name>
    <other_name>Cis-diamminedichloridoplatinum</other_name>
    <other_name>Cis-diamminedichloro Platinum (II)</other_name>
    <other_name>Cis-diamminedichloroplatinum</other_name>
    <other_name>Cis-dichloroammine Platinum (II)</other_name>
    <other_name>Cis-platinous Diamine Dichloride</other_name>
    <other_name>Cis-platinum</other_name>
    <other_name>Cis-platinum II</other_name>
    <other_name>Cis-platinum II Diamine Dichloride</other_name>
    <other_name>Cismaplat</other_name>
    <other_name>Cisplatina</other_name>
    <other_name>Cisplatinum</other_name>
    <other_name>Cisplatyl</other_name>
    <other_name>Citoplatino</other_name>
    <other_name>Citosin</other_name>
    <other_name>Cysplatyna</other_name>
    <other_name>DDP</other_name>
    <other_name>Lederplatin</other_name>
    <other_name>Metaplatin</other_name>
    <other_name>Neoplatin</other_name>
    <other_name>Peyrone''s Chloride</other_name>
    <other_name>Peyrone''s Salt</other_name>
    <other_name>Placis</other_name>
    <other_name>Plastistil</other_name>
    <other_name>Platamine</other_name>
    <other_name>Platiblastin</other_name>
    <other_name>Platiblastin-S</other_name>
    <other_name>Platinex</other_name>
    <other_name>Platinol</other_name>
    <other_name>Platinol- AQ</other_name>
    <other_name>Platinol-AQ</other_name>
    <other_name>Platinol-AQ VHA Plus</other_name>
    <other_name>Platinoxan</other_name>
    <other_name>Platinum</other_name>
    <other_name>Platinum Diamminodichloride</other_name>
    <other_name>Platiran</other_name>
    <other_name>Platistin</other_name>
    <other_name>Platosin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Decortication</intervention_name>
    <description>Undergo decortication</description>
    <arm_group_label>Arm I (Step 1: chemotherapy, P/D: Step 2: no treatment)</arm_group_label>
    <arm_group_label>Arm II (Step 1: chemotherapy, P/D, Step 2: IMRT/PBS)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Intensity-Modulated Radiation Therapy</intervention_name>
    <description>Undergo IMRT</description>
    <arm_group_label>Arm II (Step 1: chemotherapy, P/D, Step 2: IMRT/PBS)</arm_group_label>
    <other_name>IMRT</other_name>
    <other_name>Intensity Modulated RT</other_name>
    <other_name>Intensity-Modulated Radiotherapy</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pemetrexed</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Arm I (Step 1: chemotherapy, P/D: Step 2: no treatment)</arm_group_label>
    <arm_group_label>Arm II (Step 1: chemotherapy, P/D, Step 2: IMRT/PBS)</arm_group_label>
    <other_name>MTA</other_name>
    <other_name>Multitargeted Antifolate</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pemetrexed Disodium</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Arm I (Step 1: chemotherapy, P/D: Step 2: no treatment)</arm_group_label>
    <arm_group_label>Arm II (Step 1: chemotherapy, P/D, Step 2: IMRT/PBS)</arm_group_label>
    <other_name>Alimta</other_name>
    <other_name>Almita</other_name>
    <other_name>LY231514</other_name>
    <other_name>N-[4-[2-(2-Amino-4,7-dihydro-4-oxo-1H-pyrrolo[2,3-d]pyrimidin-5-yl)ethyl]benzoyl]-L-glutamic Acid Disodium Salt</other_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Pencil Beam Scanning</intervention_name>
    <description>Undergo PBS</description>
    <arm_group_label>Arm II (Step 1: chemotherapy, P/D, Step 2: IMRT/PBS)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Pleurectomy</intervention_name>
    <description>Undergo pleurectomy</description>
    <arm_group_label>Arm I (Step 1: chemotherapy, P/D: Step 2: no treatment)</arm_group_label>
    <arm_group_label>Arm II (Step 1: chemotherapy, P/D, Step 2: IMRT/PBS)</arm_group_label>
    <other_name>Excision of Pleura</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Quality-of-Life Assessment</intervention_name>
    <description>Ancillary studies</description>
    <arm_group_label>Arm I (Step 1: chemotherapy, P/D: Step 2: no treatment)</arm_group_label>
    <arm_group_label>Arm II (Step 1: chemotherapy, P/D, Step 2: IMRT/PBS)</arm_group_label>
    <other_name>Quality of Life Assessment</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Questionnaire Administration</intervention_name>
    <description>Ancillary studies</description>
    <arm_group_label>Arm I (Step 1: chemotherapy, P/D: Step 2: no treatment)</arm_group_label>
    <arm_group_label>Arm II (Step 1: chemotherapy, P/D, Step 2: IMRT/PBS)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        PRIOR TO STEP 1 REGISTRATION INCLUSION CRITERIA&#xD;
&#xD;
          -  Pathologically (histologically or cytologically) confirmed diagnosis of epithelioid or&#xD;
             biphasic malignant pleural mesothelioma (MPM) within 90 days prior to Step 1&#xD;
             Registration&#xD;
&#xD;
          -  Imaging proof of clinical stage (American Joint Committee on Cancer [AJCC] 8th&#xD;
             edition) I-IIIA MPM by PET/CT within 42 days prior to Step 1 Registration&#xD;
&#xD;
          -  MPM is amenable to resection by P/D as determined by a thoracic surgeon within 42 days&#xD;
             prior to Step 1 Registration&#xD;
&#xD;
          -  History/physical examination within 42 days prior to Step 1 Registration&#xD;
&#xD;
          -  Karnofsky performance status &gt;= 80 within 42 days prior to Step 1 Registration&#xD;
&#xD;
          -  Pulmonary function tests within 42 days prior to Step 1 Registration:&#xD;
&#xD;
               -  &gt;= 40% predicted post-forced expiratory volume in 1 second (FEV1);&#xD;
&#xD;
               -  &gt;= 40% predicted post-operative diffusion capacity of the lung for carbon&#xD;
                  monoxide (DLCO) (corrected for hemoglobin [Hgb])&#xD;
&#xD;
          -  Leukocytes &gt;= 3000 cells/mm^3 (within 30 days prior to Step 1 Registration)&#xD;
&#xD;
          -  Absolute neutrophil count &gt;= 1500 cells/mm^3 (within 30 days prior to Step 1&#xD;
             Registration)&#xD;
&#xD;
          -  Platelets &gt;= 100,000 cells/mm^3 (within 30 days prior to Step 1 Registration)&#xD;
&#xD;
          -  Serum total bilirubin =&lt; 1.5 X upper limit of normal (ULN) (within 30 days prior to&#xD;
             Step 1 Registration)&#xD;
&#xD;
          -  Aspartate aminotransferase (AST) (serum glutamic-oxaloacetic transaminase [SGOT]) and&#xD;
             alanine aminotransferase (ALT) (serum glutamate pyruvate transaminase [SGPT]) =&lt; 3.0 X&#xD;
             ULN (within 30 days prior to Step 1 Registration)&#xD;
&#xD;
          -  Glomerular filtration rate (GFR): &gt;= 50 mL/min/1.73 m^2 (must be calculated using&#xD;
             estimated creatinine clearance [CrCl] by the Cockcroft-Gault [C-G] equation [Nephron&#xD;
             1976;16:31-41]) (within 30 days prior to Step 1 Registration)&#xD;
&#xD;
          -  Negative serum pregnancy test within 14 days of Step 1 Registration for pre-menopausal&#xD;
             women of childbearing potential&#xD;
&#xD;
          -  The patient or a legally authorized representative must provide study-specific&#xD;
             informed consent prior to study entry&#xD;
&#xD;
          -  EORTC QLQ-C30 and QLQ-LC13 within 42 days prior to Step 1 Registration PRIOR TO STEP 2&#xD;
             RANDOMIZATION INCLUSION CRITERIA&#xD;
&#xD;
          -  Patients must have received at least 2 cycles of pemetrexed/platinum chemotherapy and&#xD;
             undergone a pleurectomy/decortication with the goal of macroscopic complete resection&#xD;
             following step 1 Registration&#xD;
&#xD;
          -  Karnofsky performance status &gt;= 70 within 30 days prior to Step 2 Randomization&#xD;
&#xD;
          -  History/physical examination within 30 days prior to Step 2 Randomization&#xD;
&#xD;
          -  EORTC QLQ-C30 and QLQ-LC13 within 30 days prior to Step 2 Randomization&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        PRIOR TO STEP 1 REGISTRATION EXCLUSION CRITERIA&#xD;
&#xD;
          -  Pregnant or lactating women, or sexually active men or women not using effective&#xD;
             contraception (risk for fetal defects from teratogenic chemotherapy and radiation&#xD;
             therapy) within 14 days prior to Step 1 Registration&#xD;
&#xD;
          -  Diagnosis of sarcomatoid mesothelioma&#xD;
&#xD;
          -  Severe, active co-morbidity defined as follows:&#xD;
&#xD;
               -  New York Heart Association (NYHA) class III or IV heart failure&#xD;
&#xD;
               -  Chronic obstructive pulmonary disease (COPD) requiring chronic oral steroid&#xD;
                  therapy of &gt; 10 mg prednisone daily or equivalent at the time of registration.&#xD;
                  Inhaled corticosteroids are allowed;&#xD;
&#xD;
               -  Unstable angina requiring hospitalization and/or transmural myocardial infarction&#xD;
                  within the last 3 months;&#xD;
&#xD;
               -  Interstitial lung disease;&#xD;
&#xD;
               -  Hemodialysis or peritoneal dialysis;&#xD;
&#xD;
               -  Concurrent active malignancy (with the exception of current or prior&#xD;
                  non-melanomatous skin cancer or low-grade malignancies followed observantly for&#xD;
                  which treatment has not or does not have the potential to interfere with the&#xD;
                  safety or efficacy assessment of the investigational regimen)&#xD;
&#xD;
                    -  If evidence of disease &lt; 3 years, institution must consult with the&#xD;
                       principal investigator, Andreas Rimner, Doctor of Medicine (MD)&#xD;
&#xD;
               -  Hepatic impairment defined by ChildPugh class (ChildPugh class B &amp; C);&#xD;
&#xD;
                    -  For patients with evidence of chronic hepatitis B virus (HBV) infection, the&#xD;
                       HBV viral load must be undetectable on suppressive therapy within 30 days&#xD;
                       prior to registration, if indicated. Note: HBV viral testing is not required&#xD;
                       for eligibility for this protocol&#xD;
&#xD;
                    -  Patients with a history of hepatitis C virus (HCV) infection must have been&#xD;
                       treated and cured. For patients with HCV infection who are currently on&#xD;
                       treatment, they are eligible if they have an undetectable HCV viral load&#xD;
                       within 30 days prior to registration&#xD;
&#xD;
               -  Active tuberculosis&#xD;
&#xD;
               -  Patients on immunosuppressive therapy, for example history of organ or bone&#xD;
                  marrow transplant or chronic lymphocytic leukemia (CLL);&#xD;
&#xD;
               -  CD4 count &lt; 200 cells/microliter. Note that patients who are human&#xD;
                  immunodeficiency virus (HIV) positive are eligible, provided they are under&#xD;
                  treatment with highly active antiretroviral therapy (HAART) and have a CD4 count&#xD;
                  &gt;= 200 cells/microliter within 30 days prior to registration. Note also that HIV&#xD;
                  testing is not required for eligibility for this protocol&#xD;
&#xD;
          -  Prior nephrectomy on the contralateral side of MPM&#xD;
&#xD;
          -  Ipsilateral thoracic electronic implant, e.g. pacemaker, defibrillator, unless&#xD;
             switched to the contralateral side prior to initiation of radiation therapy (RT)&#xD;
&#xD;
          -  Prior thoracic radiation therapy (patients with prior thoracic RT cannot be planned to&#xD;
             50-60 Gy without exceeding normal tissue constraints)&#xD;
&#xD;
        PRIOR TO STEP 2 RANDOMIZATION EXCLUSION CRITERIA&#xD;
&#xD;
          -  Progressive disease&#xD;
&#xD;
          -  Supplemental oxygen use&#xD;
&#xD;
          -  Third space fluid that cannot be controlled by drainage or insufficient lung expansion&#xD;
             after P/D (this prevents targeting the pleura without exceeding normal tissue&#xD;
             constraints)&#xD;
&#xD;
          -  Prior intrapleural therapy (i.e. intrapleural chemotherapy, photodynamic therapy);&#xD;
             pleurodesis is permitted&#xD;
&#xD;
          -  Bulky residual disease in the major fissure preventing pleural IMRT&#xD;
&#xD;
          -  Patients who have undergone extrapleural pneumonectomy&#xD;
&#xD;
          -  Patients with active infection that requires systemic I.V. antibiotics, antiviral, or&#xD;
             antifungal treatments&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Andreas Rimner, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>NRG Oncology</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>UM Sylvester Comprehensive Cancer Center at Coral Gables</name>
      <address>
        <city>Coral Gables</city>
        <state>Florida</state>
        <zip>33146</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Public Contact</last_name>
      <phone>305-243-2647</phone>
    </contact>
    <investigator>
      <last_name>Alan Libardi Dal Pra</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UM Sylvester Comprehensive Cancer Center at Deerfield Beach</name>
      <address>
        <city>Deerfield Beach</city>
        <state>Florida</state>
        <zip>33442</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Public Contact</last_name>
      <phone>305-243-2647</phone>
    </contact>
    <investigator>
      <last_name>Alan Libardi Dal Pra</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Miami Miller School of Medicine-Sylvester Cancer Center</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Public Contact</last_name>
      <phone>305-243-2647</phone>
    </contact>
    <investigator>
      <last_name>Alan Libardi Dal Pra</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Moffitt Cancer Center-International Plaza</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33607</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Public Contact</last_name>
      <phone>800-679-0775</phone>
      <email>ClinicalTrials@moffitt.org</email>
    </contact>
    <investigator>
      <last_name>Bradford A. Perez</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Moffitt Cancer Center - McKinley Campus</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33612</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Public Contact</last_name>
      <phone>800-679-0775</phone>
      <email>ClinicalTrials@moffitt.org</email>
    </contact>
    <investigator>
      <last_name>Bradford A. Perez</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Moffitt Cancer Center</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33612</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Public Contact</last_name>
      <phone>800-679-0775</phone>
      <email>ClinicalTrials@moffitt.org</email>
    </contact>
    <investigator>
      <last_name>Bradford A. Perez</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Chicago Comprehensive Cancer Center</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60637</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Public Contact</last_name>
      <phone>773-702-8222</phone>
      <email>cancerclinicaltrials@bsd.uchicago.edu</email>
    </contact>
    <investigator>
      <last_name>Hedy L. Kindler</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Brigham and Women's Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Public Contact</last_name>
      <phone>617-724-5200</phone>
    </contact>
    <investigator>
      <last_name>Raymond H. Mak</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic in Rochester</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Public Contact</last_name>
      <phone>855-776-0015</phone>
    </contact>
    <investigator>
      <last_name>Dawn Owen</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Basking Ridge</name>
      <address>
        <city>Basking Ridge</city>
        <state>New Jersey</state>
        <zip>07920</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Public Contact</last_name>
      <phone>212-639-7592</phone>
    </contact>
    <investigator>
      <last_name>Andreas Rimner</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Monmouth</name>
      <address>
        <city>Middletown</city>
        <state>New Jersey</state>
        <zip>07748</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Public Contact</last_name>
      <phone>212-639-7592</phone>
    </contact>
    <investigator>
      <last_name>Andreas Rimner</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Bergen</name>
      <address>
        <city>Montvale</city>
        <state>New Jersey</state>
        <zip>07645</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Public Contact</last_name>
      <phone>212-639-7592</phone>
    </contact>
    <investigator>
      <last_name>Andreas Rimner</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Commack</name>
      <address>
        <city>Commack</city>
        <state>New York</state>
        <zip>11725</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Public Contact</last_name>
      <phone>212-639-7592</phone>
    </contact>
    <investigator>
      <last_name>Andreas Rimner</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Westchester</name>
      <address>
        <city>Harrison</city>
        <state>New York</state>
        <zip>10604</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Public Contact</last_name>
      <phone>212-639-7592</phone>
    </contact>
    <investigator>
      <last_name>Andreas Rimner</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mount Sinai Hospital</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10029</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Suspended</status>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Public Contact</last_name>
      <phone>212-639-7592</phone>
    </contact>
    <investigator>
      <last_name>Andreas Rimner</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Nassau</name>
      <address>
        <city>Uniondale</city>
        <state>New York</state>
        <zip>11553</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Public Contact</last_name>
      <phone>212-639-7592</phone>
    </contact>
    <investigator>
      <last_name>Andreas Rimner</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cleveland Clinic Foundation</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Public Contact</last_name>
      <phone>866-223-8100</phone>
      <email>TaussigResearch@ccf.org</email>
    </contact>
    <investigator>
      <last_name>Gregory M. M. Videtic</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ohio State University Comprehensive Cancer Center</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43210</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Public Contact</last_name>
      <phone>800-293-5066</phone>
      <email>Jamesline@osumc.edu</email>
    </contact>
    <investigator>
      <last_name>Jeremy Brownstein</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Public Contact</last_name>
      <phone>713-798-1354</phone>
      <email>burton@bcm.edu</email>
    </contact>
    <investigator>
      <last_name>Robert T. Ripley</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Swedish Medical Center-First Hill</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98122-4307</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Public Contact</last_name>
      <phone>206-215-3086</phone>
      <email>PCRC-NCORP@Swedish.org</email>
    </contact>
    <investigator>
      <last_name>Krishna C. Alluri</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Research Institute of the McGill University Health Centre (MUHC)</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H3H 2R9</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Suspended</status>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>November 5, 2019</study_first_submitted>
  <study_first_submitted_qc>November 6, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">November 8, 2019</study_first_posted>
  <last_update_submitted>November 4, 2021</last_update_submitted>
  <last_update_submitted_qc>November 4, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 8, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Mesothelioma</keyword>
  <keyword>IMPRINT</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mesothelioma</mesh_term>
    <mesh_term>Mesothelioma, Malignant</mesh_term>
    <mesh_term>Lung Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cisplatin</mesh_term>
    <mesh_term>Carboplatin</mesh_term>
    <mesh_term>Pemetrexed</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

